Stress-inducible protein expression in chemotherapy and cancer vaccine therapy in gastrointestinal cancer
| Project/Area Number |
20591584
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Tazuke Kofukai Medical Research Institute |
|---|
Principal Investigator |
UEDA Shugo Tazuke Kofukai Medical Research Institute, 医学研究所第1研究部, 主任研究員 (80372580)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 抗癌化学療法 / がんワクチン療法 / 消化器癌 / チオレドキシン / トランスレーシ / ョナルリサーチ / トランスレーショナルリサーチ / 胃癌 / 食道癌 |
|---|
| Research Abstract |
We found that advanced gastric cancer responded to chemotherapy showed lower expression of 5-FU metabolism-related genes, such as thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD). Serum levels of thioredoxin, a stress-inducible protein, in advanced cancer patients increased one or two days after injection of anti-cancer drugs, which suggests that the serum levels may correlate with tumor decay. Advanced esophageal cancer patients treated with cancer vaccine showed increased titer of cancer antigen-specific antibody. Serum thioredoxin during cancer vaccine therapy increased along with tumor growth, suggesting that the serum levels may develop to be a novel surrogate marker of tumor volume.
|
Report
(4 results)
Research Products
(40 results)
-
-
-
-
-
-
-
[Journal Article] Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-4322009
Author(s)
Aoki M, Ueda S,Nishikawa H, Kitano S, Hirayama M, Ikeda H, Toyoda H, Tanaka K, Kanai M, Takabayashi A, Imai H, Shiraishi T, Sato E, Wada H, Nakayama E, Takei Y, Katayama N, Shiku H, Kageyama S
-
Journal Title
Vaccine 27(49)
Pages: 6854-6861
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 食道癌に対する混合ワクチンCHP-NY-ESO-1・CHP-HER2の安全性と免疫反応2008
Author(s)
青木雅俊,上田修吾,西川博嘉,平川倫子,北野滋久,池田裕明,金井陸行,高林有道,佐藤永一,竹井謙之,片山直之,珠玖洋,影山慎一
Organizer
第67回日本癌学会学術総会
Place of Presentation
名古屋
Related Report
-
-
-
-
[Presentation] Combination cancer vaccine of CHP-NY-ESO-1 and CHP-HER2 with immuno-adjuvant, OK-432, for chemorefractory metastatic or recurrent esophageal cancer patients2008
Author(s)
Shugo Ueda, Masatoshi Aoki, Hiroyoshi Nishikawa, Michiko Hirayama, Shigehisa Kitano, Eriko Hayashi, Michiyuki Kanai, Arimichi Takabayashi, Hiroshi Shiku, Shinichi Kageyama
Organizer
99th AACR Annual Meeting 2008
Place of Presentation
San Diego, USA
Related Report
-
